Therapy of chronic lymphocytic leukaemia with purine nucleoside analogues: Facts and controversies

Drugs and Aging

Volumn 22, Issue 12, 2005, Pages 983-1012

  Robak, Tadeusz ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ALEMTUZUMAB; ALKYLATING AGENT; ANTHRACYCLINE DERIVATIVE; ANTIINFECTIVE AGENT; ANTINEOPLASTIC AGENT; ANTIVIRUS AGENT; CHLORAMBUCIL; CLADRIBINE; CORTICOSTEROID; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; HEMOPOIETIC GROWTH FACTOR; IDARUBICIN; MITOXANTRONE; MONOCLONAL ANTIBODY; PENTAMIDINE; PENTOSTATIN; PREDNISONE; PURINE NUCLEOSIDE DERIVATIVE; RITUXIMAB; VALACICLOVIR; VINCRISTINE;

ACUTE GRANULOCYTIC LEUKEMIA; ALLOGENEIC STEM CELL TRANSPLANTATION; ANEMIA; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; AUTOIMMUNE HEMOLYTIC ANEMIA; AUTOLOGOUS STEM CELL TRANSPLANTATION; BLOOD DISEASE; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER RELAPSE; CHEMICAL STRUCTURE; CHILL; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; CROSS RESISTANCE; CUTANEOUS T CELL LYMPHOMA; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG ELIMINATION; DRUG ERUPTION; DRUG FEVER; DRUG FORMULATION; DRUG HALF LIFE; DRUG INDUCED CANCER; DRUG MECHANISM; DRUG POTENCY; DRUG POTENTIATION; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG UPTAKE; GASTROINTESTINAL SYMPTOM; GRAFT VERSUS HOST REACTION; GRANULOCYTOPENIA; HUMAN; HYPOTENSION; HYPOXIA; INFECTION; INFECTION PREVENTION; INTERMETHOD COMPARISON; LUNG CANCER; MALIGNANT NEOPLASTIC DISEASE; MINIMAL RESIDUAL DISEASE; MYELODYSPLASTIC SYNDROME; NAUSEA AND VOMITING; NEUTROPENIA; NONHODGKIN LYMPHOMA; NONMYELOABLATIVE CONDITIONING; NONMYELOABLATIVE STEM CELL TRANSPLANTATION; PNEUMONIA; PRIORITY JOURNAL; PURE RED CELL ANEMIA; REVIEW; RICHTER SYNDROME; SEPTIC SHOCK; SOLID TUMOR; STEM CELL MOBILIZATION; STEM CELL TRANSPLANTATION; THROMBOCYTOPENIA; WALDENSTROEM MACROGLOBULINEMIA;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DRUG ADMINISTRATION ROUTES; DRUG INTERACTIONS; DRUG RESISTANCE, NEOPLASM; HUMANS; INFECTION CONTROL; LEUKEMIA, LYMPHOCYTIC, CHRONIC; PURINE NUCLEOSIDES; RANDOMIZED CONTROLLED TRIALS; RECURRENCE; STEM CELL TRANSPLANTATION;

EID: 29244492252     PISSN: 1170229X     EISSN: 1170229X     Source Type: Journal    
DOI: 10.2165/00002512-200522120-00002     Document Type: Review

References (180)

1. Redaelli A, Laskin BL, Stephens JM, et al. The clinical and epidemiological burden of chronic lymphocytic leukaemia. Eur J Cancer Care (Engl) 2004; 13: 279-87
2. Kalil N, Cheson BD. Management of chronic lymphocytic leukemia. Drugs Aging 2000; 16: 9-27
3. Robak T. Therapy of chronic lymphocytic leukemia with purine and monoclonal antibodies. Transfus Apher Sci 2005; 32: 33-44
4. Ries LAG, Eisner MP, Kosary CL, et al., editors. SEER Cancer Statistics Review 1975-2001. Bethesda (MD): National Cancer Institute [online]. Available from URL: http://seer.cancer.gov/csr/1975_2000 [Accessed 2005 Nov 18]
5. Dighiero G, Binet JL. When and how to treat chronic lymphocytic leukemia. N Engl J Med 2000; 343: 1799-801
6. Cheson BD, Bennett JM, Grever M, et al. National Cancer Institute sponsored working group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 1996; 87: 4990-7
7. French Cooperative Group on Chronic Lymphocytic Leukemia. Natural history of stage A chronic lymphocytic leukaemia untreated patients. Br J Haematol 1990; 76: 45-57
8. Molica S. Progression and survival studies in early chronic lymphocytic leukemia. Blood 1991; 78: 895-9
9. Jaksic B, Brugiatelli M, Krc I, et al. High dose chlorambucil versus Binet's modified cyclophosphamide, doxorubicin, vincristine and prednisone regimen in the treatment of patients with advanced B-cell chronic lymphocytic leukemia: results of an international multicenter randomized trial. International Society for Chemo-Immunotherapy, Vienna. Cancer 1997; 79: 2107-14
10. Robak T, Bloński JZ, Kasznicki M, et al. Cladribine with prednisone versus chlorambucil with prednisone as first-line therapy in chronic lymphocytic leukemia: report of a prospective, randomized, multicenter trial. Blood 2000; 96: 2723-9
11. Rai KR, Peterson BL, Appelbaum FR, et al. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl J Med 2000; 343: 1750-7
12. Dighiero G, Maloum K, Desablens B, et al. Chlorambucil in indolent chronic lymphocytic leukemia. N Engl J Med 1998; 338: 1506-14
13. Robak T, Kasznicki M. Alkylating agents and nucleoside analogues in the treatment of B-cell chronic lymphocytic leukemia. Leukemia 2002; 16: 1015-27
14. Tallman MS, Hakimian D. Purine nucleoside analogs: emerging roles in indolent lymphoproliferative disorders. Blood 1995; 86: 2463-74
15. Zinzani PL. Non-Hodgkin's lymphoma: the evolving role of purine analogues. Best Pract Res Clin Haematol 2002; 15: 505-16
16. Johnson SA, Oscier DG, Leblond V. Waldenstrom's macroglobulinaemia. Blood Rev 2002; 16: 175-84
17. Evens AM, Gartenhaus RB. Treatment of T-cell non-Hodgkin's lymphoma. Curr Treat Options Oncol 2004; 5: 289-303
18. Lauria F, Forconi F. Towards the pharmacotherapy of hairy cell leukemia. Expert Opin Pharmacother 2004; 5: 1523-33
19. Robak T. Purine nucleoside analogues in the treatment of myeloid leukemias. Leuk Lymphoma 2003; 44: 391-409
20. Pastor-Anglada M, Molina-Arcas M, Casado FJ, et al. Nucleoside transporters in chronic lymphocytic leukemia. Leukemia 2004; 18: 385-92
21. Molina-Arcas N, Marce S, Villamor N, et al. Equilibrative nucleoside transporter-2 (hENT2) protein expression correlates with ex vivo sensitivity to fludarabine in chronic lymphocytic leukemia (CLL) cells. Leukemia 2005; 19: 64-8
22. Plunkett W, Saunders PP. Metabolism and action of purine nucleoside analogues. Pharmacol Ther 1991; 49: 239-68
23. Pettit AR. Mechanism of action of purine analogues in chronic lymphocytic leukemia. Br J Haematol 2003; 121: 692-702
24. Genini D, Adachi S, Chao O, et al. Deoxyadenosine analogs induced programmed cell death in chronic lymphocytic leukemia cells by damaging the DNA and by directly affecting the mitochondria. Blood 2000; 96: 3537-43
25. Marzo I, Perez-Galan P, Rubio-Felix D, et al. Cladribine induces apoptosis in human leukemia cells by caspase dependent and independent pathways acting on mitochondria. Biochem J 2001; 359: 537-46
26. Klopfer A, Hasenjager A, Belka C, et al. Adenine deoxynucleotides fludarabine and cladribine induce apoptosis in a CD95/Fas receptor, FADD and caspase-8-independent manner by activation of the mitochondrial cell death pathway. Oncogene 2004; 16: 9408-18
27. Johnston JB, Daeninck P, Verburg L, et al. P53, MDM-2, BAX and BCL-2 and drug resistance in chronic lymphocytic leukemia. Leuk Lymphoma 1997; 26: 435-49
28. Genini D, Budihardjo I, Plunkett W, et al. Nucleotide requirements for the in vitro activation of the apoptosis protein activating factor-1 mediated caspase pathway. J Biol Chem 2000; 275: 29-34
29. Adkins JC, Peters DH, Markham A. Fludarabine: an update of its pharmacology and use in the treatment of haematological malignancies. Drugs 1997; 53: 1005-37
30. Beutler E. Cladribine (2-chlorodeoxyadenosine). Lancet 1992; 340: 952-6
31. Aldinucci D, Poletto D, Lorenzon D, et al. CD26 expression correlates with a reduced sensitivity to 2′-deoxycoformycin induced growth inhibition and apoptosis in T-cell leukemia/lymphomas. Clin Cancer Res 2004; 10: 508-20
32. Niitsu N, Yamaguchi Y, Umeda M, et al. Human monocytoid leukemia cells are highly sensitive to apoptosis induced by 2′-deoxycoformycin and 2′-deoxyadenosine: association with dATP-dependent activation of caspase-3. Blood 1998; 92: 3368-75
33. Gandhi V, Plunkett W. Cellular and clinical pharmacology of fludarabine. Clin Pharmacokinetics 2002; 41: 93-103
34. Foran JM, Oscier D, Orchard J, et al. Pharmacokinetic study of single doses of oral fludarabine phosphate in patients with 'low-grade' non-Hodgkin's lymphoma and B-cell chronic lymphocytic leukemia. J Clin Oncol 1999; 17: 1574-9
35. Boogaerts MA. Oral fludarabine therapy in chronic lymphocytic leukemia: increased convenience. Hematol J 2004; 5 Suppl. 1: S31-7
36. Robak T. Cladribine in the treatment of chronic lymphocytic leukemia. Leuk Lymphoma 2001; 40: 551-64
37. Liliemark J, Juliusson G. On the pharmacokinetics of 2-chloro-2′- deoxyadenosine in humans. Cancer Res 1991; 51: 5570-2
38. Liliemark J, Albertioni F, Hassan M, et al. On the bioavailability of oral and subcutaneous 2-chloro-2′-deoxyadenosine in humans: alternative routes of administration. J Clin Oncol 1992; 10: 1514-8
39. Saven A, Cheung WK, Smith I, et al. Pharmacokinetic study of oral and bolus intravenous 2-chlorodeoxyadenosine in patients with malignancy. J Clin Oncol 1996; 14: 978-83
40. Lindemalm S, Savic RM, Karlsson MO, et al. Application of population pharmacokinetics to cladribine. BMC Pharmacol 2005 Mar 9; 5 (1): 4
41. O'Dwyer PJ, Wagner B, Leyland-Jones B, et al. 2′-deoxycoformycin (pentostatin) for lymphoid malignancies: rational development of an active new drug. Ann Intern Med 1988; 108: 733-43
42. Begleiter A, Wang H, Verburg L, et al. In vitro cytotoxicity of 2-chlorodeoxyadenosine and chlorambucil in chronic lymphocytic leukemia. Leukemia 1996; 10: 1959-65
43. Szmigielska-Kaplon A, Ciesielska E, Szmigiero L, et al. Anthracyclines potentiate activity against murine leukemias L1210 and P388 in vivo and in vitro. Eur J Haematol 2002; 68: 370-5
44. Smolewski P, Szmigielska-Kaplon A, Cebula B, et al. Proapoptotic activity of alemtuzumab alone and in combination with rituximab or purine nucleoside analogues in chronic lymphocytic leukemia cells. Leuk Lymphoma 2005; 46: 87-100
45. Bellosillo B, Villamor N, Colomer D, et al. In vitro evaluation of fludarabine in combination with cyclophosphamide and/or mitoxantrone in B-cell chronic lymphocytic leukemia. Blood 1999; 94: 2836-43
46. Szmigielska-Kaplon A, Smolewski P, Najder M, et al. Evaluation of apoptosis induced in vitro by cladribine (cladribine) combined with anthracyclines in lymphocytes from patients with B-cell chronic lymphocytic leukemia. Ann Hematol 2002; 81: 508-13
47. Klein A, Miera O, Bauer O, et al. Chemosensitivity of B-cell chronic lymphocytic leukemia and correlated expression of proteins regulating apoptosis, cell cycle and DNA repair. Leukemia 2000; 14: 40-6
48. Robak T, Blasinska-Morawiec M, Blonski J, et al. 2-Chlorode-oxyadenosine (cladribine) in the treatment of hairy cell leukemia and hairy cell leukemia variant: 7-year experience in Poland. Eur J Haematol 1999; 62: 49-56
49. Bergmann L, Fenchel K, Jahn B, et al. Immunosuppressive effects and clinical response of fludarabine in refractory chronic lymphocytic leukemia. Ann Oncol 1993; 4: 371-5
50. Seymour JF, Kurzrock R, Freireich EJ, et al. 2-chlorodeoxyadenosine induces durable remissions and prolonged suppression of CD4+ lymphocyte counts in patients with hairy cell leukemia. Blood 1994; 83: 2906-11
51. Anaissie EJ, Kontoyiannis DP, O'Brien S, et al. Infections in patients with chronic lymphocytic leukemia treated with fludarabine Ann Intern Med 1998; 129: 559-66
52. Cheson BD. Infections and immunosuppressive complications of purine analog therapy. J Clin Oncol 1995; 13: 2431-48
53. Van den Neste E, Delannoy A, Vandercam B. Infectious complications after 2-chlorodeoxyadenosine therapy. Eur J Haematol 1996; 56: 235-40
54. Mauro FR, Foa R, Cerretti R, et al. Autoimmune hemolytic anemia in chronic lymphocytic leukaemia: clinical, therapeutic and prognostic features. Blood 2000; 95: 2786-92
55. Johnson S, Smith AG, Loffler H, et al. Multicentre prospective randomised trial of fludarabine versus cyclophosphamide, doxorubicin and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukaemia. The French Cooperative Group on CLL. Lancet 1996; 347: 1432-8
56. Leporrier M, Chevret S, Cazin B, et al. French Cooperative Group on Chronic Lymphocytic Leukemia. Randomized comparison of fludarabine, CAP, and CHOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients. Blood 2001; 98: 2319-25
57. Leporrier M, Reman O, Troussard X. Pure red-cell aplasia with fludarabine for chronic lymphocytic leukemia [letter]. Lancet 1993; 342: 555
58. Robak T, Kasznicki M, Blonski JZ, et al. Pure red cell aplasia with chronic lymphocytic leukaemia treated with cladribine. Br J Haematol 2001; 112: 1083-5
59. Kroft SH, Tallman MS, Shaw JM, et al. Myelodysplasia following treatment of chronic lymphocytic leukemia (CLL) with 2-chlorodeoxyadenosine (cladribine). Leukemia 1997; 11: 170
60. Van Den Neste E, Louviaux I, Michaux JL, et al. Myelodysplastic syndrome with monosomy 5 and/or 7 following therapy with 2-chloro-2′- deoxyadenosine. Br J Haematol 1999; 105: 268-70
61. Robak T. Second malignancies and Richter's syndrome in patients with chronic lymphocytic leukemia. Hematology 2004; 9: 387-400
62. Cheson BD, Vena DA, Barrett J, et al. Second malignancies as a consequence of nucleoside analog therapy for chronic lymphoid leukemias. J Clin Oncol 1999; 17: 2454-60
63. Robak T, Blonski JZ, Gora-Tybor J, et al. Second malignancies and Richter's syndrome in patients with chronic lymphocytic leukemia treated with cladribine. Eur J Cancer 2004; 40: 383-9
64. Tsimberidou AM, Keating MJ. Richter syndrome: biology, incidence, and therapeutic strategies. Cancer 2005; 103: 216-28
65. Pocock C, Matutes E, Wotherspoon A, et al. Fludarabine therapy may precipitate large cell transformation in chronic lymphocytic leukaemia but not in follicular lymphoma [abstract no. 1774]. Blood 1998; 92 Suppl. 1: 429a
66. Giles FJ, O'Brien SM, Keating MJ. Chronic lymphocytic leukemia in Richter's transformation. Semin Oncol 1998; 25: 117-25
67. Robertson LE, Pugh W, O'Brien S, et al. Richter's syndrome: a report on 39 patients. J Clin Oncol 1993; 11: 1985-9
68. Van den Neste E, Dellanoy A, Feremans W, et al. Second primary tumors and immune phenomena after fludarabine or 2-chloro-2′-deoxyadenosine treatment. Leuk Lymphoma 2001; 40: 541-50
69. Keating MJ, O'Brien S, Lerner S, et al. Long-term follow-up of patients with chronic lymphocytic leukemia (CLL) receiving fludarabine regimens as initial therapy. Blood 1998; 92: 1165-71
70. Robak T, Bloński JZ, Kasznicki M, et al. Cladribine with or without prednisone in the treatment of previously treated and untreated B-cell chronic lymphocytic leukemia: updated results of the multicenter study of 378 patients. Br J Haematol 2000; 108: 357-68
71. Keating MJ, O'Brien S, Kantarjian H, et al. Long term follow-up of patients with chronic lymphocytic leukemia treated with fludarabine as a single agent. Blood 1993; 81: 2878-84
72. Piro LD, Carrera CJ, Beutler E, et al. 2-Chlorodeoxyadenosine: an effective new agent for the treatment of chronic lymphocytic leukemia. Blood 1988; 71: 1069-73
73. Dillman RO, Mick R, McIntyre OR. Pentostatin in chronic lymphocytic leukemia: a phase II trial of Cancer and Leukemia Group B. J Clin Oncol 1989; 7: 433-8
74. Dearden C, Catovsky D. Deoxycoformycin in the treatment of mature B-cell malignancies. Br J Cancer 1990; 62: 4-5
75. Dillman RO. Pentostatin (nipent) in the treatment of chronic lymphocyte leukemia and hairy cell leukemia. Expert Rev Anticancer Ther 2004; 4: 27-36
76. Spriano M, Chiorazzi F, Liso V, et al. Multicentre prospective randomized trial of fludarabine versus chlorambucil and prednisone in previously untreated patients with active B-CLL: final report [abstract no. PO86]. Hematol Cell Ther 2000; 42: 93
77. Jaksic B, Brugiatelli M, Suciu S, et al. Fludarabine versus high-dose continuous chlorambucil in untreated patients with B-CLL: results of CLL1 EORTC randomized trial [abstract P096]. Haematol Cell Ther 2000; 42: 97
78. Dohner H, Fisher K, Bentz M, et al. P 53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias. Blood 1995; 85: 1580-9
79. Wattel E, Preudhome C, Hecquet B, et al. p53 mutations are associated with resistance to chemotherapy and short survival in hematologic malignancies. Blood 1994; 84: 3148-57
80. Rosenwald A, Chuang EY, Davis RE, et al. Fludarabine treatment of patients with chronic lymphocytic leukemia induces a p53 dependent gene expression response. Blood 2004; 104: 1428-34
81. Begleiter A, Verburg L, Ashique A, et al. Comparison of antitumor activities of 2-chlorodeoxyadenosine and 9-B-arabinosyl-2-fluoroadenine in chronic lymphocytic leukemia and marrow cells in vitro. Leukemia 1995; 9: 1875-81
82. Koski T, Vilpo L, Vilpo J. Chemosensitivity in vitro to 2-chlorodeoxyadenosine and 9-B-D-arabinofuranosyl-2-fluoroadenine in previously unexposed cases of chronic lymphocytic leukemia. Leuk Res 1999; 23: 277-9
83. Tondini C, Balzarotti M, Ramoinelli I, et al. Fludarabine and cladribine in relapsed/refractory low-grade non-Hodgkin's lymphoma: a phase II randomized study. Ann Oncol 2000; 11: 231-3
84. Karlsson K, Stromberg M, Jonsson V. Cladribine (CdA) or fludarabine (F) or high-dose intermittent chlorambucil (Chl) as first-line treatment of symptomatic chronic lymphocytic leukemia: first interim analysis of data from the international randomized phase III trial [abstract no. 3470]. Blood 2004; 104 Suppl. 1: 945a
85. Robak T, Bloński JZ, Góra-Tybor J, et al. Cladribine with cyclophosphamide vs. fludarabine with cyclophosphamide as first-line treatment in chronic lymphocytic leukemia: an early report of prospective randomized study (PALG CLL3) [abstract no. 364]. Hematologica Hematol J 2005; 90 Suppl. 2: 143-4
86. Morabito F, Stelitano C, Callea I, et al. In vitro sensitivity of chronic lymphocytic leukemia B-cells to fludarabine, 2-chlorodeoxyadenosine and chlorambucil: correlation with clinico-hematological and immunophenotypic features. Haematologica 1996; 81: 224-31
87. Juliusson G, Elmhorn-Rosenborg A, Liliemark J. Response to 2-chlorodeoxyadenosine in patients with B-cell chronic lymphocytic leukemia resistant to fludarabine. N Engl J Med 1992; 327: 1056-61
88. Byrd JC, Peterson B, Piro L, et al. A phase II study of cladribine treatment for fludarabine refractory cell chronic lymphocytic leukemia: results from CALGB Study 9211. Leukemia 2003; 17: 323-7
89. O'Brien S, Kantarjian H, Estey E, et al. Lack of effect of 2-chlorodeoxyadenosine therapy in patients with chronic lymphocytic leukemia refractory to fludarabine therapy. N Engl J Med 1994; 330: 319-22
90. O'Brien S, Kantarjian H, Beran M, et al. Results of fludarabine and prednisone therapy in 264 patients with chronic lymphocytic leukemia with multivariate analysis: derived prognostic model for response to treatment. Blood 1993; 82: 1690-700
91. Robak T, Szmigielska A. Dexamethasone does not enhance antileukemic activity of cladribine in mice with leukemias L1210 and P388. Neoplasma 2000; 47: 168-71
92. Robak T, Blasinska-Morawiec M, B JZ, et al. The effect of 2-h infusion of 2-chlorodeoxyadenosine (cladribine) with prednisone in previously untreated B-cell chronic lymphocytic leukaemia. Eur J Cancer 1997; 33: 2347-51
93. Góra-Tybor J, Robak T. Synergistic action of 2-chlorodeoxy- adenosine and cyclophosphamide on murine leukemias L1210 and P388. Acta Haematol Pol 1993; 24: 177-82
94. Van Den Neste E, Bontemps F, Delacauw A, et al. Potentiation of antitumor effect of cyclophosphamide derivatives in B-chronic lymphocytic leukemia cells by 2-chloro-2′-deoxyadenosine. Leukemia 1999; 13: 918-25
95. Van Den Neste E, Louviaux I, Michaux JL, et al. Phase I/II study of 2-chloro-2′-deoxyadenosine with cyclophosphamide in patients with pretreated B cell chronic lymphocytic leukemia and indolent non-Hodgkin's lymphoma. Leukemia 2000; 14: 1136-42
96. Montillo M, Tedeschi A, O'Brien S, et al. Phase II study of cladribine and cyclophosphamide in patients with chronic lymphocytic leukemia and prolymphocytic leukemia. Cancer 2003; 97: 114-20
97. Robak T, Blonski JZ, Kasznicki M, et al. Cladribine combined with cyclophosphamide is highly effective in the treatment of chronic lymphocytic leukemia. Hematol J 2002; 3: 244-50
98. O'Brien S, Kantarjian HM, Cortes J, et al. Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia. J Clin Oncol 2001; 19: 1414-20
99. Hallek M, Schmitt B, Wilhelm M, et al. Fludarabine plus cyclophosphamide is an efficient treatment for advanced chronic lymphocytic leukaemia (CLL): results of a phase II study of the German CLL Study Group. Br J Haematol 2001; 14: 342-8
100. Eichhorst BF, Hopfinger G, Pasold R, et al. Fludarabine plus cyclophosphamide (FC) induces higher remission rates and longer progression free survival (PFS) than fludarabine (F) alone in first line therapy of advanced chronic lymphocytic leukemia (CLL): results of a phase III study (CLL 4 protocol) of the German CLL Study Group (GLLL SG) [abstract no. 243]. Blood 2003; 102: 72a
101. Cazin B, Maloum K, Divine M, et al. Oral fludarabine and cyclophosphamide in previously untreated CLL: preliminary data on 75 pts [abstract no. 773]. Blood 2002; 100 (11 Pt 1): 206a
102. Bosch F, Ferrer A, Lopez-Guillermo A, et al. Fludarabine, cyclophosphamide and mitoxantrone in the treatment of resistant or relapsed chronic lymphocytic leukemia. Br J Haematol 2002; 119: 976-84
103. Robak T, Bloński JZ, Kasznicki M, et al. Cladribine combined with cyclophosphamide and mitoxantrone as front-line therapy in chronic lymphocytic leukemia. Leukemia 2001; 15: 1510-6
104. Weiss MA, Maślak PG, Jurcic JG, et al. Pentostatin and cyclophosphamide: an effective new regimen in previously treated patients with chronic lymphocytic leukemia. J Clin Oncol 2003; 21: 1278-84
105. Robak T, Góra-Tybor J, Lech-Marańda E, et al. Cladribine in combination with mitoxantrone and cyclophosphamide (CMC) in the treatment of heavily pre-treated patients with advanced indolent lymphoid malignancies. Eur J Haematol 2001; 66: 188-94
106. Robak T, Bloński JZ, Góra-Tybor J, et al. Cladribine alone or in combination with cyclophosphamide or cyclophosphamide and mitoxantrone as first line treatment in chronic lymphocytic leukemia: an early report of a prospective, randomized study [abstract no. 337]. Blood 2004; 104: 100a
107. Hallek M, Eichhorst BF. Chemotherapy combination treatment regimens with fludarabine in chronic lymphocytic leukemia. Hematol J 2004; 5 Suppl. 1: S20-30
108. Nabhan C, Gartenhaus RB, Tallman MS. Purine nucleoside analogues and combination therapies in B-cell chronic lymphocytic leukemia: dawn of a new era. Leuk Res 2004; 28: 429-42
109. Alas S, Bonavida B, Emmanoulides C. Potentiation of fludarabine cytotoxicity on non-Hodgkin's lymphoma by pentoxifylline and rituximab. Anticancer Res 2000; 20: 2961-6
110. Di Gaetano N, Xiao Y, Erba E, et al. Synergism between fludarabine and rituximab revealed in a follicular lymphoma cell line resistant to the cytotoxic activity of either drug alone. Br J Haematol 2001; 114: 800-9
111. Robak T. Alemtuzumab in the treatment of chronic lymphocytic leukemia. Biodrugs 2005; 19: 9-22
112. Schulz H, Klein SK, Rehwald U, et al. Phase 2 study of a combined immunochemotherapy using rituximab and fludarabine in patients with chronic lymphocytic leukemia. Blood 2002; 100: 3115-20
113. Savage DG, Cohen NS, Hesdorffer CS, et al. Combined fludarabine and rituximab for low grade lymphoma and chronic lymphocytic leukemia. Leuk Lymphoma 2003; 44: 477-81
114. Byrd JC, Peterson BL, Morrison VA, et al. Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALG B9712). Blood 2003; 101: 6-14
115. Byrd JC, Rai K, Peterson BL, et al. Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukaemia: an updated retrospective analysis of CALGB 9712 and CALGB 9011. Blood 2005; 105: 49-53
116. Keating MJ, O'Brien S, Albitar M, et al. Early results of chemoimmunotherapy regimen of fludarabine, cyclophosphamide and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol 2005; 29: 4079-88
117. Wierda W, O'Brien S, Wen S, et al. Chemoimmunotherapy with fludarabine, cyclophosphamide and rituximab for relapsed and refractory chronic lymphocytic leukemia. J Clin Oncol 2005; 23: 4070-8
118. Robak T, Smolewski P, Urbańska-Ryś H, et al. Rituximab followed by cladribine in the treatment of heavily pretreated patients with indolent lymphoid malignancies. Leuk Lymphoma 2004; 45: 937-44
119. Tsiara SN, Kapsali HD, Chaidos A, et al. Treatment of resistant/relapsing chronic lymphocytic leukemia with a combination regimen containing deoxycoformycin and rituximab. Acta Haematol 2004; 111: 185-8
120. Kay E, Geyer SN, Lin T, et al. Combination chemotherapy with pentostatin, cyclophosphamide and rituximab induces high rate of remissions including complete responses and achievement of minimal residual disease in previously untreated Bchronic lymphocytic leukemia [abstract no. 339]. Blood 2004, 104; 100a
121. Kennedy B, Rawstron A, Carter C, et al. Campath-1H and fludarabine in combination are highly active in refractory chronic lymphocytic leukaemia. Blood 2002; 99: 2245-7
122. Elter T, Borchmann P, Reiser M, et al. Development of a new four weekly schedule (FluCam) with concomitant application of Campath-1H and fludarabine in patients with relapsed/refractory CLL [abstract no. 2331]. Proc Am Soc Clin Oncol 2003; 22: 580
123. Rai KR, Byrd JC, Peterson BL, et al. A phase II trial of fludarabine followed by alemtuzumab (Campath-1H) in previously untreated chronic lymphocytic leukemia (CLL) patients with active disease: Cancer and Leukemia Group B (CALGB) Study 199 [abstract no. 772]. Blood 2002; 100 Suppl. 1: 205a
124. Wendtner CM, Ritgen M, Schweighofer CD, et al. Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission: experience of safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG). Leukemia 2004; 18: 1093-101
125. Moreton P, Kennedy B, Lucas G, et al. Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival. J Clin Oncol 2005; 23: 2971-9
126. Tedeschi A, Montillo M, Cairoli E, et al. Successful CD34+ priming with intermediate-dose Ara-C (ID Ara-C) in chronic lymphocytic leukemia (CLL) patients treated with sequential fludarabine (FAMP) and Campath-1 H [abstract no. 3277]. Blood 2002; 100 Suppl. 1: 830a
127. Dyer MJ, Kelsey SM, Mackay HJ, et al. In vivo 'purging' of residual disease in CLL with Campath-1H. Br J Haematol 1997; 97: 669-72
128. Montillo M, Cafro AM, Tedeschi A, et al. Safety and efficacy of subcutaneous Campath-1H for treating residual disease in patients with chronic lymphocytic leukemia responding to fludarabine. Haematologica 2002; 87: 695-700
129. Magnac C, Sutton L, Cazin B, et al. Detection of minimal residual disease in B chronic lymphocytic leukemia (CLL). Hematol Cell Ther 1999; 41: 13-8
130. Khouri IE, Keating MJ, Saliba MR, et al. Long-term follow-up of patients with CLL treated with allogenic hematopoietic transplantation. Cytotherapy 2002; 4: 217-21
131. Schultze JL, Donovan JW, Gribben JG. Minimal residual disease detection after myeloablative chemotherapy in chronic lymphotic leukemia. J Mol Med 1999; 77: 259-65
132. Ritgen M, Bottcher S, Dregor P, et al. Evaluation of minimal residual disease in chronic lymphocytic leukemia. Haematologica Res 2005; 1 Suppl. 2: 5-8
133. Esteve J, Villamor N, Colomer D, et al. Stem cell transplantation for chronic lymphocytic leukemia: different outcomes after autologous and allogenic transplantation and correlation with minimal residual disease status. Ann Oncol 1998; 9: 167-77
134. Sutton L, Maloum K, Gonzalez H, et al. Autologous hematopoietic stem cell transplantation as salvage treatment for advanced B cell chronic lymphocytic leukemia. Leukemia 1998; 12: 1699-707
135. Pfitzner T, Reiser M, Barth S, et al. Quantitative molecular monitoring of residual tumor cells in chronic lymphocytic leukemia. Ann Hematol 2002; 81: 258-66
136. Clavio M, Miglino M, Spriano M, et al. First line fludarabine treatment of symptomatic chronic lymphoproliferative diseases: clinical results and molecular analysis of minimal residual disease. Eur J Haematol 1998; 61: 197-203
137. Esteve J, Villamor N, Colomer D, et al. Hematopoietic stem cell transplantation in chronic lymphocytic leukemia: a report of 12 patients from a single institution. Ann Oncol 1998; 9: 167-72
138. Robertson LE, Huh YO, Butler JJ, et al. Response assessment in chronic lymphocytic leukemia after fludarabine plus prednisone: clinical, pathologic, immunophenotypic and molecular analysis. Blood 1997; 80: 29-36
139. Cazin BF, Maloum K, Creteil MD, et al. Oral fludarabine phosphate and cyclophosphamide in previously untreated CLL: final response and follow-up in 75 patients [abstract no. 1598]. Blood 2003; 102: 438a
140. Bosch F, Ferrer A, Lopez-Guillermo A, et al. Fludarabine cyclophosphamide and mitoxantrone in the treatment of resistant or relapsed chronic lymphocytic leukemia. Br J Haematol 2002; 119: 976-84
141. Robak T, Bloński JZ, Kasznicki M, et al. Cladribine combined with cyclophosphamide is highly effective in the treatment of chronic lymphocytic leukemia. Hematol J 2002; 3: 244-50
142. Oscier D, Orchard JA, Culligan D, et al. The bioavailability of oral fludarabine phosphate is unaffected by food. Hematol J 2001; 2: 316-21
143. Boogaerts MA, Van Hoof A, Catovsky D, et al. Activity of oral fludarabine phosphate in previously treated chronic lymphocytic leukemia. J Clin Oncol 2001; 19: 4252-8
144. Rossi JF, van Hoof A, De Boeck K, et al. Efficacy and safety of oral fludarabine phosphate in previously untreated patients with chronic lymphocytic leukemia. J Clin Oncol 2004; 22: 1260-7
145. Friedberg JW, Dong DA, Li S, et al. Oral fludarabine has significant activity in patients with previously untreated chronic lymphocytic leukemia and leads to increased STAT1 levels in vivo. Leuk Res 2004; 28: 139-47
146. Juliusson G, Christiansen I, Hansen MM, et al. Oral cladribine as primary therapy for patients with B-cell chronic lymphocytic leukemia. J Clin Oncol 1996; 14: 2160-6
147. Karlsson K, Stromberg N, Liliemark J, et al. Oral cladribine for B-cell chronic lymphocytic leukemia: report of a phase II trial with a 3-d, 3-weekly schedule in untreated and pretreated patients and a long-term follow up of 126 previously treated patients. Br J Hematol 2002; 116: 538-48
148. Betticher DC, Ratschiller D, Hsu Schmitz SF, et al. Reduced dose of subcutaneous cladribine induces identical response rates but decreased toxicity in pretreated chronic lymphocytic leukemia. Ann Oncol 1998; 9: 721-6
149. Samonis G, Kontoyiannis DP. Infectious complications of purine analog therapy. Curr Opin Infect Dis 2001; 14: 409-13
150. O'Brien S. Infectious complications of nucleoside analogs: hematology. Educational Book of the American Society of Hematology Meeting; 1999 Dec 3-7; New Orleans, 536-42
151. Anaissie EJ, Kontoyiannis DP, O'Brien S, et al. Infections in patients with chronic lymphocytic leukemia treated with fludarabine. Ann Intern Med 1998; 129: 559-66
152. Perkins JG, Flynn JM, Howard RS, et al. Frequency and type of serious infections in fludarabine-refractory B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma: implications for clinical trials in this patient population. Cancer 2002; 94: 2033-9
153. Cheson BD. Infectious and immunosuppressive complications of purine analog therapy. J Clin Oncol 1995; 13: 2431-48
154. O'Brien S, Kantarjian H, Beran M, et al. Fludarabine and granulocyte colony stimulating factor (G-CSF) in patients with chronic lymphocytic leukemia. Leukemia 1997; 11: 1631-5
155. Sudhoff T, Arning M, Schneider W. Prophylactic strategies to meet infectious complications in fludarabine treated CLL. Leukemia 1997; 11 Suppl. 2: S38-41
156. Byrd JC, Hargis JB, Kester KE, et al. Opportunistic pulmonary infections with fludarabine in previously treated patients with low-grade lymphoid malignancies: a role for Pneumocystic carinii pneumonia prophylaxis. Am J Hematol 1995; 49: 135-42
157. Robak T, Blonski JZ, Kasznicki M, et al. The effect of subsequent therapies in patients with chronic lymphocytic leukemia previously treated with prednisone and either cladribine or chlorambucil. Haematologica 2005; 90: 994-6
158. Balcer AM. The management of leukemia in elderly. Bailliere's Clin Haematol 1997; 1: 427-48
159. Spiers ASD. Management of the chronic leukemias: Special considerations in the elderly patient. Part I. Chronic lymphocytic leukemias. Hematology 2001; 6: 291-314
160. Robak T, Blonski J, Kasznicki M, et al. Comparison of cladribine plus prednisone with chlorambucil plus prednisone in patients with chronic lymphocytic leukemia: final report of the Polish Adult Leukemia Study Group (PALG CLL 1). Med Sci Monit 2005; 11 (10): PI71-9
161. Shvidel L, Shtalrid M, Bairey O, et al. Conventional dose fludarabine-based regimens are effective but have excessive toxicity in elderly patients with refractory chronic lymphocytic leukemia. Leuk Lymphoma 2003; 44: 1947-50
162. Marotta G, Bigazz C, Lenoci M, et al. Low dose fludarabine and cyclophosphamide in elderly patients with B-cell chronic lymphocytic leukemia refractory to conventional therapy. Haematologica 2000; 85: 1268-70
163. Robak T, Blasinska-Morawiec M, Blonski JZ, et al. 2-chlorode-oxyadenosine (cladribine) in the treatment of elderly patients with B-cell chronic lymphocytic leukemia. Leuk Lymphoma 1999; 34: 151-7
164. Thomas DA, O'Brien SM, Kantarjian HM, et al. Re-treatment with fludarabine: outcome of 203 patients with relapsed or refractory CLL treated with salvage therapy [abstract no. PO84]. Hematol Cell Ther 2000; 42: 92
165. Juliusson G, Liliemark J. Retreatment of chronic lymphocytic leukemia with 2-chlorodeoxyadenosine (CdA) at relapse following CdA induced remission: no
166. Robak T, Bloński JZ, Kasznicki M, et al. Re-treatment with cladribine based regimens in relapsed patients with B-cell chronic lymphocytic leukemia: efficacy and toxicity in comparison with previous treatment. Eur J Haematol 2002; 69: 27-36
167. Keating MJ, Flinn I, Jain V, et al. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: result of a large international study. Blood 2002; 99: 3554-61
168. Rai KR, Freter CE, Mercier RJ, et al. Alemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received fludarabine. J Clin Oncol 2002; 20: 3891-7
169. Sorror ML, Maris MB, Sandmaier BM, et al. Hematopoietic cell transplantation after nonmyeloablative conditioning for advanced chronic lymphocytic leukemia. J Clin Oncol 2005; 23: 3819-29
170. Schetelig J, Thiede C, Bornhouser M, et al. Evidence for a graft versus leukemia effect in chronic lymphocytic leukemia after reduced intensity conditioning and allogenic stem-cell transplantation: the Cooperative German Transplant Study Group. J Clin Oncol 2003; 14: 2747-53
171. Khouri IF, Lee MS, Saliba RM, et al. Nonablative allogenic stem cell transplantation for chronic lymphocytic leukemia: impact of rituximab on immunomodulation and survival. Exp Hematol 2004; 32: 28-35
172. Dreger P, Brand R, Mulligan D, et al. Reduced intensity conditioning lowers treatment related mortality of allogenic stem cell transplantation for chronic lymphocytic leukemia: a population matched analysis. Leukemia 2005; 19: 1029-33
173. Pensesha S, Milligan DW. Stem cell transplantation for chronic lymphocytic leukemia. Br J Haematol 2005; 128: 145-52
174. Rizouli V, Gribben JG. The role of stem cell transplantation in chronic lymphocytic leukemia. Semin Hematol 2004; 41: 2416-53
175. Michallet M, Thiebaut A, Dreger P, et al. Peripheral blood stem cell (PBSC) mobilization and transplantation after fludarabine therapy in chronic lymphocytic leukemia (CLL): a report of the European Blood and Marrow Transplantation (EBMT) CLL subcommittee on behalf of the EBMT Chronic Leukemias Working Party (CLWP). Br J Haematol 2000; 108: 595-601
176. Tournilhac O, Cazin B, Lepretre S, et al. Impact of front line fludarabine and cyclophosphamide combined treatment on peripheral blood stem cell mobilization in B-cell chronic lymphocytic leukemia. Blood 2004; 103: 363-5
177. Lysak D, Koza V, Steinerova K, et al. Mobilization of peripheral blood stem cells in CLL patients after front-line fludarabine treatment. Ann Hematol 2005; 84: 456-61
178. Wijermans PW, Gerrits WB, Haak HL. Severe immunodeficiency in patients treated with fludarabine monophosphate. Eur J Haematol 1993; 50: 292-6
179. Dreger P, Montserrat E. Autologous and allogenic stem cell transplantation for chronic lymphocytic leukemia. Leukemia 2002; 16: 985-92
180. Montserrat E. Role of auto-and allotransplantation in B-cell chronic lymphocytic leukemia. Hematol Oncol Clin N Am 2004; 18: 915-26